Executive Search Success Story: Recruiting Scientific Leadership for a Cell & Gene Therapy Company

How JRG Partners executed a confidential, multi-role North American retained search strategy for a rapidly growing biosciences company scaling cell and gene therapy research after key clinical milestones, balancing innovation, compliance, and commercialization.

The Challenge

A rapidly growing biosciences company specializing in cell and gene therapy research was preparing for its next phase of expansion after several clinical milestones and increased investor funding. To protect its progress and successfully execute its growth roadmap, the enterprise needed to balance innovation, compliance, and commercialization. Corporate leadership identified several critical structural and market pressures:

• Difficulty scaling research and development operations
• Competition for specialized scientific talent
• Regulatory complexity associated with clinical programs
• Leadership gaps across translational research
• Pressure to accelerate development timelines
• Succession concerns among senior scientific leaders

The company’s executive leadership determined that stabilizing and advancing their operations required a synchronized corporate management structure spanning a Chief Scientific Officer, VP Research & Development, VP Clinical Development, VP Regulatory Affairs, Director of Translational Sciences, Director of Program Management, and scientific leaders. Successfully executing this multi-role mandate required an executive search partner combining technical vertical literacy in life sciences with deep cell & gene therapy expertise and a direct line to a national pool of passive talent.

Why They Chose JRG Partners

Deep Cell & Gene Therapy Specialization

Unlike generalist recruiting agencies that lack functional immersion in highly complex regulatory environments, JRG Partners maintains dedicated search practices explicitly focused on cell and gene therapy, R&D, clinical development, translational science, and regulatory leadership standards required to support continuous advancement.

Real Access to Passive Talent

Many of the strongest scientific leaders and quality executives are typically fully integrated into high-performing corporate systems, meaning they rarely monitor traditional job listings. JRG Partners bypassed conventional recruitment channels entirely, leveraging long-standing relationships, proprietary market intelligence, and executive networks to directly engage high-performing passive leaders invisible to standard sourcing methods.

Confidential Search Execution

Because this leadership architecture was built during a sensitive growth phase with clinical programs and investor milestones at stake, absolute discretion was mandatory. JRG Partners deployed a highly secure, confidential vetting and outreach framework that successfully insulated the client’s strategic positioning, protected active program continuity, and maintained total candidate trust throughout the transition lifecycle.

True Nationwide Sourcing Reach

Sourcing specialized scientific executives capable of unceasingly advancing a complex development footprint required an outreach strategy unconstrained by regional borders. JRG Partners executed a coordinated talent acquisition strategy across major life-sciences hubs throughout North America, providing corporate sponsors with an elite shortlist of proven, lateral talent.

Our Corporate Search Strategy

Phase 1 — Leadership Assessment & Strategic Alignment

Our consultants partnered directly with the CEO, Board, and executive team to systematically map existing organizational gaps, identify hidden succession risks, clarify growth objectives, and define the exact leadership competencies required for long-term scaling. Rather than matching candidates against legacy job descriptions, we built forward-looking executive profiles dynamically tied to the enterprise’s long-term corporate expansion strategy.

Phase 2 — Multi-Sector Market Mapping

JRG Partners executed an exhaustive market-mapping initiative that targeted high-performing, process-driven scientific environments across the continent. Our comprehensive market map targeted key talent pools across biotechnology companies, cell and gene therapy organizations, pharmaceutical companies, academic research institutions, life sciences startups, contract research organizations, and clinical-stage bioscience firms.

Phase 3 — Targeted Executive Engagement

Using a research-driven, highly discreet outreach framework, our consultants directly contacted and evaluated high-achieving corporate leaders with verified records of success in drug development, translational research, and cross-functional team management. Only candidates demonstrating clear, measurable operational impact and rigorous scientific fluency advanced to the final evaluation round.

Phase 4 — Rigorous Assessment & Final Selection

Each finalist candidate underwent an extensive evaluation process looking far beyond basic professional credentials. Our consultants conversion-tested strategic and functional capabilities, regulatory compliance agility, team-building and leadership philosophies, cross-functional communication skills, cultural alignment with rapid innovation timelines, and long-term retention potential.

Key Outcomes

• 450+ targeted biotechnology, pharma, and cell and gene therapy executive profiles systematically mapped across major North American life-sciences and commercial hubs.
• Successfully placed and integrated a complete corporate and scientific leadership framework—spanning the Chief Scientific Officer, vice presidents, and directors—within a 12-month timeline.
• Unified separate research and program functions under a single, cohesive corporate strategy by installing process-driven transformation executives.
• Accelerated development timelines and standardized research facility practices by placing forward-thinking translational and clinical leaders.
• Mitigated long-term operational risks and optimized submission readiness by placing specialized, data-driven regulatory affairs executives.
• Protected crucial clinical data, sensitive proprietary pipelines, and expansion metrics during a high-stakes transition phase through strict search confidentiality.
• Provided the Board of Directors and CEO with a high-performance management framework explicitly equipped to eliminate leadership gaps and drive profitable, compliant clinical innovation at scale.